

# Eugene M Laska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/860779/publications.pdf>

Version: 2024-02-01

23  
papers

758  
citations

840776  
11  
h-index

752698  
20  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1311  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying subtypes of PTSD to promote precision medicine. <i>Neuropsychopharmacology</i> , 2022, 47, 379-380.	5.4	0
2	A likely responder approach for the analysis of randomized controlled trials. <i>Contemporary Clinical Trials</i> , 2022, 114, 106688.	1.8	1
3	Pre-deployment risk factors for PTSD in active-duty personnel deployed to Afghanistan: a machine-learning approach for analyzing multivariate predictors. <i>Molecular Psychiatry</i> , 2021, 26, 5011-5022.	7.9	55
4	Posttraumatic stress disorder symptom trajectories within the first year following emergency department admissions: pooled results from the International Consortium to predict PTSD. <i>Psychological Medicine</i> , 2021, 51, 1129-1139.	4.5	32
5	Utilization of machine learning for identifying symptom severity military-related PTSD subtypes and their biological correlates. <i>Translational Psychiatry</i> , 2021, 11, 227.	4.8	11
6	CRF serum levels differentiate PTSD from healthy controls and TBI in military veterans. <i>Psychiatric Research and Clinical Practice</i> , 2021, 3, 153-162.	2.4	7
7	Gabapentin Enacarbil Extended-release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1875-1884.	2.4	12
8	Predeployment neurocognitive functioning predicts postdeployment posttraumatic stress in Army personnel. <i>Neuropsychology</i> , 2020, 34, 276-287.	1.3	22
9	S17. Pre-Deployment Risk Factors for PTSD in Afghanistan Veterans: A Machine Learning Approach for Analyzing Multivariate Predictors. <i>Biological Psychiatry</i> , 2019, 85, S302-S303.	1.3	0
10	Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). <i>Contemporary Clinical Trials</i> , 2019, 81, 102-109.	1.8	9
11	Speech-based markers for posttraumatic stress disorder in US veterans. <i>Depression and Anxiety</i> , 2019, 36, 607-616.	4.1	70
12	Estimating the risk of PTSD in recent trauma survivors: results of the International Consortium to Predict PTSD (ICPP). <i>World Psychiatry</i> , 2019, 18, 77-87.	10.4	126
13	Electrical fingerprint of the amygdala guides neurofeedback training for stress resilience. <i>Nature Human Behaviour</i> , 2019, 3, 63-73.	12.0	82
14	Application of data pooling to longitudinal studies of early post-traumatic stress disorder (PTSD): the International Consortium to Predict PTSD (ICPP) project. <i>Høgskole Utbildning</i> , 2018, 9, 1476442.	3.0	18
15	The nonlinear relationship between cerebrospinal fluid A $\beta$ 242 and tau in preclinical Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0191240.	2.5	41
16	The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings. <i>Contemporary Clinical Trials</i> , 2016, 48, 166-172.	1.8	20
17	Prevalence and Diagnosis Rates of Childhood ADHD Among Racial-Ethnic Groups in a Public Mental Health System. <i>Psychiatric Services</i> , 2016, 67, 199-205.	2.0	12
18	Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. <i>Addiction</i> , 2015, 110, 1008-1014.	3.3	81

#	ARTICLE	IF	CITATIONS
19	Outcomes of The BODY Project: A Program to Halt Obesity and Its Medical Consequences in High School Students. Journal of Community Health, 2015, 40, 1149-1154.	3.8	1
20	Model-based multiplicity estimation of population size. Statistics in Medicine, 2009, 28, 2230-2252.	1.6	2
21	Assessing Onset of Treatment Benefit in Depression and Anxiety. Journal of Clinical Psychiatry, 2009, 70, 1138-1145.	2.2	2
22	Statistical Inference for Cost-Effectiveness Ratios. , 1997, 6, 229-242.		75
23	Oral analgesic studies: Pentazocine hydrochloride, codeine, aspirin, and placebo and their influence on response to placebo. Clinical Pharmacology and Therapeutics, 1966, 7, 447-454.	4.7	79